Beta Bionics, Inc. (BBNX) Key Metrics
BBNX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $882.0M
- Enterprise value
- $1.02B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 7.4
- Price / book
- 4.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
BBNX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBBNX returns How much profit the business earns on the capital it uses.
BBNX per-share figures Results divided by the shares outstanding at year-end.
BBNX financial health Debt, liquidity and how easily interest is covered.
BBNX efficiency & capital use Working capital cycle and where the cash goes.
BBNX valuation history
BBNX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BBNX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BBNX price vs earnings per share
BBNX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $1.23B | — | — | — |
| Enterprise value | $1.02B | — | — | — |
| Price / sales | 12.3 | — | — | — |
| Price / book | 4.3 | — | — | — |
| EV / sales | 10.2 | — | — | — |
| Earnings yield | −5.9% | — | — | — |
| Free cash flow yield | −4.6% | — | — | — |
| Share price at fiscal year-end | $30.47 | — | — | — |
| Per share | ||||
| Revenue per share | $2.47 | $1.52 | $0.28 | $0.00 |
| Earnings per share | −$1.81 | −$1.28 | −$1.03 | −$1.51 |
| Operating cash flow per share | −$1.26 | −$1.13 | −$0.76 | −$1.40 |
| Free cash flow per share | −$1.39 | −$1.21 | −$0.77 | −$1.42 |
| Cash per share | $5.41 | $2.42 | $2.26 | $0.65 |
| Book value per share | $7.10 | $1.77 | $1.37 | −$3.97 |
| Tangible book value per share | $7.10 | $1.77 | $1.37 | −$3.97 |
| Capex per share | $0.13 | $0.08 | $0.01 | $0.02 |
| Debt per share | $0.18 | $0.17 | $0.10 | $0.10 |
| Shares outstanding | 40.5M | 42.9M | 42.9M | 42.9M |
| Change in shares outstanding | −5.4% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −40.3% | −81.3% | — | — |
| Return on invested capital (ROIC) | −204.1% | — | — | — |
| Return on assets (ROA) | −30.6% | −42.2% | −60.6% | −182.3% |
| Return on tangible assets | −22.3% | −36.6% | −40.1% | −182.3% |
| Free cash flow margin | −56.1% | −79.3% | −273.8% | — |
| Financial health | ||||
| Total debt | $7.3M | $7.3M | $4.2M | $4.1M |
| Cash & short-term investments | $219.1M | $103.6M | $96.7M | $27.7M |
| Net debt | −$211.8M | −$96.3M | −$92.5M | −$23.5M |
| Debt / equity | 0.03 | 0.10 | 0.07 | — |
| Debt / assets | 0.02 | 0.05 | 0.04 | 0.12 |
| Current ratio | 8.66 | 6.29 | 9.77 | 3.21 |
| Quick ratio | 7.96 | 5.66 | 9.65 | 3.21 |
| Interest coverage | — | — | -527.2 | — |
| Working capital | $237.0M | $111.8M | $93.0M | $19.6M |
| Invested capital | $75.8M | −$20.3M | −$33.9M | −$193.6M |
| Tangible asset value | $287.6M | $76.0M | $58.6M | −$170.0M |
| Net current asset value | $226.8M | $59.3M | $52.2M | −$177.1M |
| Graham net-net per share | $5.03 | $1.06 | $1.15 | −$4.15 |
| Capital allocation | ||||
| Capex / revenue | 5.3% | 5.2% | 3.4% | 431.3% |
| Capex / depreciation | 1.84 | 1.49 | 0.19 | 0.37 |
| Stock-based compensation / revenue | 16.3% | 9.8% | 47.2% | 3,407.8% |
| R&D / revenue | 34.7% | 40.2% | 149.6% | 17,557.5% |
| SG&A / revenue | 92.2% | 84.4% | 201.9% | 18,712.3% |
| Efficiency | ||||
| Days sales outstanding | 58.1 | 46.1 | 67.7 | 0.0 |
| Days of inventory on hand | 143.0 | 90.9 | 40.0 | — |
| Days payables outstanding | 32.0 | 25.1 | 51.2 | — |
| Cash conversion cycle (days) | 169.0 | 111.9 | 56.4 | — |
| Receivables turnover | 6.29 | 7.92 | 5.39 | — |
| Payables turnover | 11.39 | 14.55 | 7.13 | 0.00 |
| Inventory turnover | 2.55 | 4.01 | 9.14 | — |
| Asset turnover | 0.42 | 0.50 | 0.16 | 0.01 |
| Average receivables | $15.9M | $8.2M | $2.2M | $0 |
| Average payables | $3.9M | $2.0M | $798,000 | $430,000 |
| Average inventory | $17.5M | $7.3M | $622,500 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BBNX's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BBNX valuation and financial ratios
Beta Bionics earned a return on equity of −40.3% and a return on invested capital of −204.1% in fiscal 2025. It ended the year with $7.3 million of debt and $219.1 million in cash and short-term investments, a net cash position of $211.8 million.
See the BBNX income statement, the BBNX chart for price history, or the BBNX stock overview for the latest quote and news.
BBNX key metrics FAQ
What is Beta Bionics's return on equity?
Beta Bionics's return on equity (ROE) was −40.3% in fiscal 2025: net income of -$73.2 million on average shareholders' equity of $181.8 million.
What is Beta Bionics's ROIC?
Beta Bionics's return on invested capital was −204.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Beta Bionics have?
Beta Bionics had total debt of $7.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Beta Bionics's free cash flow yield?
Beta Bionics generated -$56.2 million of free cash flow in fiscal 2025, a free cash flow yield of −4.6% on its market value at year-end ($1.2 billion).
What is Beta Bionics's current ratio?
Beta Bionics's current ratio was 8.66 at the end of fiscal 2025: current assets were 8.66 times current liabilities.